Location Directory

Clinical trials in Phoenix, Arizona

This page shows live ClinicalTrials.gov search results for Phoenix, Arizona, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

8145

Shown on this page

Current sort

Institutions in Phoenix

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Mayo Clinic

Live official records

Open in full search

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: Quemliclustat, Placebo, Nab-paclitaxel, Gemcitabine; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 49
States / cities: Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 41 more

Conditions: Gastrointestinal Tract Malignancies
Interventions: Domvanalimab, Quemliclustat, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 17
States / cities: Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 12 more

Conditions: Prostate Cancer
Interventions: Proton Radiation Hypofractionation, Proton Radiation Standard Fractionation; Radiation
Lead sponsor: Proton Collaborative Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 5
States / cities: Phoenix, Arizona • Warrenville, Illinois • Baltimore, Maryland + 2 more

Conditions: Endometrial Cancer, Cervical Cancer, Atypical Endometrial Hyperplasia, Cervical Dysplasia, Adnexal Mass, Ovarian Cancer
Interventions: Vaginal Fluid Collection, Blood Collection; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3,110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 25
States / cities: Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 21 more

Conditions: Fragile X Syndrome
Interventions: Low dose of MRM-3379, Middle Dose of MRM-3379, High dose of MRM-3379, Placebo, Low dose of MRM-3379 Open-Label; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 13 Years to 45 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 15
States / cities: Phoenix, Arizona • Irvine, California • Orange, California + 12 more

Conditions: HER2 Positive Breast Cancer
Interventions: Tucatinib, Trastuzumab, Pertuzumab, Combination product: Trastuzumab + Pertuzumab, Placebo; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 654 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 76
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 45 more

Conditions: High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Interventions: azenosertib; Drug
Lead sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 43
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more

Conditions: X-linked Retinoschisis
Interventions: ATSN-201; Biological
Lead sponsor: Atsena Therapeutics Inc.; Industry
Eligibility: 5 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 18
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 14 more

Conditions: Adults With Overweight/Obesity and Type 2 Diabetes
Interventions: AT673 low dose, AT673 high dose, Placebo; Drug
Lead sponsor: Antag Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 8
States / cities: Chandler, Arizona • Anaheim, California • Hollywood, Florida + 5 more

Conditions: Benign Prostatic Hyperplasia (BPH)
Interventions: iTind, UroLift; Device · Procedure
Lead sponsor: Olympus Corporation of the Americas; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 15
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 12 more

Conditions: Respiratory Syncytial Virus
Interventions: Placebo, mRNA-1345; Drug
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 36,814 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 133
States / cities: Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 114 more

Conditions: Relapsed Refractory Multiple Myeloma
Interventions: AZD0120, Daratumumab, Carfilzomib, Dexamethasone, Bortezomib, Pomalidomide; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 48
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 40 more

Clinical trials in Phoenix, Arizona

Filter and sort this location

Institutions in Phoenix

Live official records

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis

A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity

Post-Market Study to Assess iTind Safety in Comparison to UroLift

A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)